Arvinas Inc
ARVNHealthcare|Biotechnology|USA
$8.28
-0.27 (-3.10%)
Tangible Book
$6.00
Clinical Trials (26)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Breast Cancer | P3 | Active | 59 | RCT, Open-label | Vepdegestrant (ARV-471/PF-07850327), Letrozole |
| NCT05654623 A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer | Advanced Breast Cancer | P3 | Active | 624 | RCT, Open-label | ARV-471, Fulvestrant |
| NCT06206837 A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | Breast Cancer | P1P2 | Active | 71 | Open-label | vepdegestrant, PF-07220060 |
| NCT07023731 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | KRAS G12D Mutation, Advanced Solid Cancer | P1P2 | Active | 159 | Open-label | ARV-806 |
| NCT05548127 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | Breast Cancer | P1P2 | Active | 37 | Open-label | ARV-471, Abemaciclib |
| NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | Breast Cancer | P1P2 | Active | 20 | Open-label | ARV-471, Ribociclib |
| NCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Breast Cancer | P1P2 | Active | 11 | Open-label | vepdegestrant, Samuraciclib |
| NCT06393738 A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | P1 | Recruiting | 255 | Open-label | ARV-393, Glofitamab |
| NCT07231991 A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function | Healthy Participants | P1 | Recruiting | 24 | Open-label | vepdegestrant |
| NCT05463952 A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) | Breast Neoplasms | P1 | Active | 6 | Open-label | vepdegestrant |
| NCT04072952 A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | Breast Cancer | P1P2 | Completed | 217 | Open-label | ARV-471, ARV-471 in combination with palbociclib (IBRANCE®) |
| NCT05549505 A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | Breast Cancer | P2 | Completed | 152 | RCT, Open-label | ARV-471, Anastrozole |
| NCT03888612 Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer | Prostate Cancer Metastatic | P1P2 | Completed | 248 | Open-label | ARV-110 |
| NCT06347861 A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults | Healthy | P1 | Completed | 52 | RCT, Open-label | single dose of vepdegestrant as tablet formulation (Treatment A), single dose of vepdegestrant as tablet formulation (Treatment B), single dose of vepdegestrant as tablet formulation (Treatment C) |
| NCT06911788 A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults | Healthy Participants | P1 | Completed | 10 | Open-label | Vepdegestrant (Reference), Vepdegestrant (Test) |
| NCT05930925 A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults | Healthy | P1 | Completed | 12 | RCT, Open-label | [phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471 |
| NCT06275841 A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant | Healthy | P1 | Completed | 12 | Open-label | vepdegestrant, esomeprazole |
| NCT05538312 A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults | Healthy | P1 | Completed | 12 | Open-label | vepdegestrant, Itraconazole |
| NCT06645938 A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults | Healthy | P1 | Completed | 12 | RCT, Open-label | single dose of vepdegestrant as tablet formulation (Treatment A), single dose of vepdegestrant as tablet formulation (Treatment B) |
| NCT05673889 A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults | Healthy | P1 | Completed | 24 | Open-label | ARV-471, Dabigatran etexilate |
| NCT05732428 A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China | Breast Cancer | P1 | Completed | 9 | Open-label | ARV-471 |
| NCT05501769 ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer | Breast Cancer | P1 | Completed | 32 | Open-label | ARV-471 in combination with Everolimus |
| NCT05652660 A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults | Healthy | P1 | Completed | 12 | Open-label | ARV-471, Rosuvastatin |
| NCT06256510 A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam | Healthy Participants | P1 | Completed | 15 | Open-label | Midazolam, Vepdegestrant |
| NCT06005688 A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants | Healthy Participants | P1 | Completed | 12 | Open-label | Vepdegestrant, Carbamazepine |
| NCT05177042 Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer | Prostate Cancer Metastatic | P1 | Completed | 45 | Open-label | Bavdegalutamide, Abiraterone |